STOCKS TELEGRAPH

Tag: Viking

  • Viking Therapeutics (VKTX) Shares Climb On Robust Quarterly Performance

    Viking Therapeutics (VKTX) Shares Climb On Robust Quarterly Performance

    Following the release of financial results, Viking Therapeutics, Inc. (NASDAQ: VKTX) shares witnessed a significant rise on the US stock charts. As observed in the after-market session on Wednesday, VKTX stock experienced a remarkable increase of 19.62%, reaching $60.30.

    Financial Performance and Clinical Pipeline Updates

    Viking Therapeutics (VKTX) revealed its financial results for the first quarter and first half of 2024, demonstrating notable progress in its clinical pipeline and commercial strategies. VKTX is getting ready for the next stages of each program after releasing encouraging findings from three distinct clinical trials.

    Notably, the Phase 2 VENTURE study of VK2735 for obesity showcased an impressive reduction in body weight by approximately 15% from baseline after 13 weeks of dosing, coupled with promising safety and tolerability.

    Viking Therapeutics is moving this compound into Phase 3 development in response to input from an FDA Type C conference. VKTX is getting ready for what is expected to be an end-of-Phase 2 meeting with the government later this year.

    Progress in Clinical Trials and Upcoming Initiatives

    Separately, following 28 days of daily oral dosage, patients in the Phase 1 trial of the oral tablet formulation of VK2735 reported an average weight reduction of up to 5.3% from baseline, indicating favorable safety, tolerability, and positive clinical activity. The process of increasing the dosage is still under progress, and later this year, Viking Therapeutics intends to launch a Phase 2 study for this program.

    Strong Financial Position for Viking and Strategic Outlook

    Viking Therapeutics concluded the quarter with a robust balance sheet of $942 million, providing the financial runway to achieve key milestones for each of its pipeline programs. During the second quarter, Viking received written responses to an FDA Type C meeting packet submitted earlier in the quarter.

    Based on the agency’s feedback, Viking Therapeutics intends to advance VK2735 into a Phase 3 program for obesity. Details regarding the Phase 3 trial design and timing will be disclosed following the end-of-Phase 2 meeting expected later this year.

  • Viking therapeutics, Inc. (VKTX) Stock Trending Higher Following Successful Phase 1 VK0214 Clinical Trial Results

    Viking therapeutics, Inc. (VKTX) Stock Trending Higher Following Successful Phase 1 VK0214 Clinical Trial Results

    Viking Therapeutics, Inc. (VKTX) stock prices were up by a marginal 0.83% as of the market closing on June 16th, 2021, bringing the price per share up to USD$6.08 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by a more significant 5.10%, bringing it up to USD$6.39.

    VK0214 Clinical Trial

    The company announced on June 17th, 2021 the results from its Phase 1 clinical trial of VK0214, the unique, orally available small molecule thyroid receptor beta agonist. Having been both single ascending dose and multiple ascending doses, the trial was designed for the development of the treatment for X-linked adrenoleukodystrophy (X-ALD). As per the results of the study, VK0214 demonstrated promising safety and tolerability, as well as a predictable pharmacokinetic (PK) profile. The initiation of Phase 1b of the study of VK0214 in X-ALD patients is set to commence in the upcoming weeks.

    Details of the Study

    The Phase 1 trial was a double-blind, placebo-controlled study of randomized healthy volunteers, with a primary objective of evaluating the safety and tolerability of VK0214 administered orally over the course of 14 days. The evaluation of the pharmacokinetics of the treatment following single and multiple doses was the secondary objective of the study.

    Layout of the Study

    The first portion of the study was designed to evaluate single doses of the treatment, with the second portion seeing the administering of VK0214 once daily to the study subjects for a period of 14 days. Both parts of the study reported subsequent cohorts having received higher doses of the treatment successfully.

    Results of the Trial

    The safety profile of VK0214 was consolidated, with a demonstrated tolerability at all the doses that were evaluated in the study. There were no serious adverse events reported; and no study-related trends were observed for changes in vital signs, gastrointestinal effects, cardiovascular measures, or physical examinations. The treatment demonstrated exposures that were dose-dependent, with no evidence of accumulation subsequent to multiple doses. The half-life of the treatment was also found to be consistent with expected dosing regimens of once a day.

    Peripheral Findings

    Potential pharmacodynamic effects following exposure to the treatment were determined by laboratory assessments that included a lipid panel. The findings indicated exposure to VK0214 resulted in a reduction in LDL-C triglycerides and apolipoprotein B after 14 days of treatment at all dosage levels. While the study wasn’t powered for it, it did achieve statistical significant in many of the observed lipid reductions.

    Future Outlook for VKTX

    Armed with the promising development of its flagship treatment, VKTX is poised to continue its trajectory of success. The company is keen to push for the commercialization and proliferation of VK0214. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.